Posted on 11/06/2014 in News, Press Releases
Pathway Genomics announced that world-renowned endocrinologist Dr. Glenn D. Braunstein has joined Pathway Genomics’ medical advisory board. Dr. Braunstein is currently the vice president of clinical innovation, director of the Thyroid Cancer Center and professor of medicine at Cedars-Sinai. For 26 years he served as chair of the Department of Medicine at Cedars-Sinai, and holds the James R. Klinenberg, M.D., Chair in Medicine.
“We are honored to have Dr. Braunstein on our medical advisory board, and we look forward to his expert contributions as we rapidly grow our commercial and research divisions,” said Jim Plante, Pathway Genomics’ founder and CEO. “His vast knowledge and veteran experience in medicine will help us continue to enhance and deliver clinically useful genetic tests to physicians and patients.”
Posted on 10/02/2014 in Blog Post
SAN DIEGO, CA
– October 2. 2014
– Genetic testing provides the opportunity to gain all sorts of insight--from the potential to diagnose rare diseases, to providing targeted therapies, to prevention. Although we have historically focused on the use of genetic testing for diagnosis, less attention has been given to genetic testing’s clinical use in preventing disease and managing health.
In the US, only 2% of the population has ever undergone genetic testing. However many studies show that the majority of patients and physicians believe that genetic testing is on the rise and that a significantly higher portion of the population could benefit from genetic testing to help identify risk for and even diagnose preventable conditions.